chronic infection or long-term liver disease.
A. Identification
1.
Acute HAV infection is usually symptomatic. Symptoms and signs can be mild to fulminant and include malaise, anorexia, fever, dark urine, pale stools, jaundice, right upper quadrant pain, and tender hepatomegaly.
2.
All patients with the above symptoms should have a hepatic function panel (CPL 9175) done initially. Elevated ALT, AST, bilirubin, and INR are consistent with hepatic involvement and form a baseline for monitoring.
3.
The presence of anti-HAV IgM in the serum confirms the diagnosis of acute Hepatitis A infection. Anti-HAV IgM is detectable within 5 to 10 days of the onset of symptoms and persists for up to 6 months.
4.
The presence of anti-HAV IgG is indicative of previous infection with HAV and confers immunity.
B. Isolation
Offenders with acute Hepatitis A should be considered contagious until 10 days after the onset of jaundice. Isolation in a single cell with a separate sink and toilet are recommended until clinical improvement and resolution of diarrhea occurs. The offender should be educated about strict hand washing and other practical infection control measures, and universal precautions are to be observed.
C. Treatment
There is no specific treatment for HAV infection. The disease is self-limited, and only 0.1% of patients have a fatal, fulminant course. Supportive measures include adequate nutrition and hydration, avoidance of hepatotoxins, rest and antiemetics as needed.
D. Immunization
Hepatitis A vaccine is administered intramuscularly in a two-dose series, 12 months apart. Hepatitis A vaccine should not be administered to inmates with hypersensitivity to alum or other components of the vaccine.
The following are indications for Hepatitis A vaccine: Broad-based prophylaxis in consultation with OSDH if the source-case was a foodhandler.
6.
Persons with known immunity to HAV (positive anti-HAV IgG) do not require prophylaxis.
Post-exposure prophylaxis consists of pooled serum immunoglobulin (IG) 0.02 ml/kg administered intramuscularly in a single dose. This should be administered within 2 weeks of exposure.
II. Hepatitis B
Hepatitis B virus (HBV) is a bloodborne pathogen. It is predominantly transmitted sexually, but is also frequently transmitted by injection drug use or other percutaneous or mucosal exposures to blood or other infectious body fluids. Perinatal transmission from mother to child also occurs. Acute hepatitis B is usually self-limited. About 2-6% of adults with HBV infection progress to chronic infection. The majority of persons with chronic HBV infection are asymptomatic, and one third has no evidence of liver disease. The remainders have chronic hepatitis ranging from mild to severe that can lead to cirrhosis and hepatocellular carcinoma (HCC). Those with chronic HBV infection have a 15-20% lifetime risk of death from cirrhosis or HCC. levels are > 2X the upper limit of normal, the patient should have a liver biopsy.
e. Liver biopsy -Patients with a necrosis score on liver biopsy of >4 may be candidates for treatment. (On the Knodell Histology Activity Index, the periportal/bridging necrosis score will be >4).
f. Consideration of antiviral therapy for chronic HBV should be individualized, taking into account that 25% of patients with chronic HBV will spontaneously clear the virus. The likelihood of response to treatment is increased in the following persons: 1) low HBV DNA levels, 2) high ALT levels, 3) short durations of infection, 4) acquisition of infection in adulthood.
g.
In summary, the criteria for consideration of treatment of chronic HBV infection are below. Consultation with Hepatology or Infectious Disease is recommended prior to treatment. Treatment of HBV is often not curative, but is used to suppress the viral activity of the HBC Chronic infection. Long term treatment may be indicated for viral suppression; to prevent secondary complications which may include Cirrhosis, HCC, Glomerulonephritis, and Polyarteritis Nodosa. 
